WallStSmart

Abbott Laboratories (ABT)vsSeaboard Corporation (SEB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 351% more annual revenue ($44.33B vs $9.82B). ABT leads profitability with a 14.7% profit margin vs 4.0%. SEB appears more attractively valued with a PEG of 0.65. SEB earns a higher WallStSmart Score of 65/100 (B-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

SEB

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 4.5Value: 10.0Quality: 8.5
Piotroski: 5/9Altman Z: 3.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
SEBUndervalued (+71.0%)

Margin of Safety

+71.0%

Fair Value

$19183.79

Current Price

$5405.30

$13778.49 discount

UndervaluedFair: $19183.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

SEB5 strengths · Avg: 9.6/10
P/E RatioValuation
9.8x10/10

Attractively priced relative to earnings

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
67.5%10/10

Earnings expanding 67.5% YoY

Altman Z-ScoreHealth
3.5910/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.658/10

Growing faster than its price suggests

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SEB2 concerns · Avg: 3.0/10
Profit MarginProfitability
4.0%3/10

4.0% margin — thin

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SEB

The strongest argument for SEB centers on P/E Ratio, Price/Book, EPS Growth. Revenue growth of 14.5% demonstrates continued momentum. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : SEB

The primary concerns for SEB are Profit Margin, Operating Margin. Thin 4.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

ABT carries more volatility with a beta of 0.74 — expect wider price swings.

SEB is growing revenue faster at 14.5% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SEB scores higher overall (65/100 vs 51/100) and 14.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Seaboard Corporation

INDUSTRIALS · CONGLOMERATES · USA

Seaboard Corporation is a global agribusiness and transportation company. The company is headquartered in Merriam, Kansas.

Visit Website →

Want to dig deeper into these stocks?